skin disease: Any deviation from the normal structure or function of the skin or subcutaneous tissue that is manifested by a characteristic set of symptoms and signs.
Acquired keratosis [keratoderma] palmaris et plantaris
DOID EFO Endpoint Browser PheWeb
L12_ACQKERAT
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
177 |
4. Check minimum number of eventsNone |
177 |
5. Include endpointsNone |
177 |
6. Filter based on genotype QC (FinnGen only) |
162 |
Control definitions (FinnGen only)
- Control exclude
- L12_OTHERSKINSUBCUTIS
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- L85
- Name in latin
- Keratosis (keratoderma) palmaris et plantaris acquisita
Similar endpoints
↥List of similar endpoints to
Acquired keratosis [keratoderma] palmaris et plantaris
based on the number of shared cases.
Similar with more cases:
- Other epidermal thickening
- Other disorders of skin and subcutaneous tissue
- Diseases of the skin and subcutaneous tissue
- Any prescribed medicine buy
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1124 | 601 | 516 |
| Only index persons | 982 | 536 | 446 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.02 | 0.02 | 0.01 |
| Only index persons | 0.02 | 0.02 | 0.02 |
| Median age at first event (years) | |||
| Whole population | 54.60 | 57.17 | 51.70 |
| Only index persons | 54.36 | 56.87 | 51.33 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 162 | 90 | 72 |
| Unadjusted period prevalence (%) | 0.03 | 0.03 | 0.03 |
| Median age at first event (years) | 56.15 | 57.74 | 54.16 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 170
- Matched controls
- 1700
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
L85.1
ICD-10 Finland
Acquired keratosis [keratoderma] palmaris et plantaris
+∞
199.6
150
*
D05BB02
ATC
acitretin; oral
65.2
112.1
65
16
D07XC01
ATC
betamethasone; topical
20.7
92.1
98
105
D02AE01
ATC
carbamide; topical
12.6
41.8
47
50
D07AD01
ATC
clobetasol; topical
8.0
39.4
75
152
E0000UV, ,
ATC
8.8
37.3
133
493
D07AC01
ATC
betamethasone; topical
5.5
26.5
109
419
L30.9
ICD-10 Finland
Dermatitis, unspecified
5.5
26.0
75
215
XQ802
NOMESCO Finland
Epicutan test
11.1
25.2
29
31
E000003, ,
ATC
10.0
22.6
28
33
D07AC13
ATC
mometasone; topical
4.3
19.8
86
327
E000001, ,
ATC
4.0
15.0
57
192
D05AX52
ATC
calcipotriol, combinations; topical
6.8
14.8
25
42
L30.8
ICD-10 Finland
Other specified dermatitis
13.1
14.4
25
22
Z01.5
ICD-10 Finland
Diagnostic skin and sensitization tests
4.7
13.5
36
92
E000006, ,
ATC
5.5
12.9
27
56
D05AX02
ATC
calcipotriol; topical
11.9
12.7
23
22
L85.9
ICD-10 Finland
Epidermal thickening, unspecified
+∞
12.7
12
*
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
5.3
12.4
27
58
D07BC01
ATC
betamethasone and antiseptics; topical
4.2
11.6
36
103
7011A
ICD-9 Finland
Other hypertrophic and atrophic conditions of skin, Keratoderma, acquired[KERATODERMA PALMARE ET PLANTARE ACQUISITUM]
+∞
11.6
11
*
TQW80
NOMESCO Finland
Local dermatologic skincare
18.7
11.5
17
10
L40.3
ICD-10 Finland
Pustulosis palmaris et plantaris
25.2
10.4
14
6
D07BB04
ATC
hydrocortisone butyrate and antiseptics; topical
3.7
10.4
38
122
XQ848
NOMESCO Finland
Dermatological photography
10.4
9.5
18
19
Q82.82
ICD-10 Finland
Inherited keratosis palmaris et plantaris
+∞
8.4
8
*
70110
ICD-8 Finland
Other hypertrophic and atrophic conditions of the skin, Keratoderma acquisitum (Kämmen, jalkapohja) (palmare, plantare)
+∞
8.4
8
*
L30.3
ICD-10 Finland
Infective dermatitis
9.0
7.5
15
18
D01BA02
ATC
terbinafine; oral
2.5
6.9
59
300
D07AB02
ATC
hydrocortisone butyrate; topical
2.4
6.8
64
340
J01CE08
ATC
benzathine benzylpenicillin; parenteral
23.6
6.7
9
*
B35.3
ICD-10 Finland
Tinea pedis
4.5
6.7
17
41
A46
ICD-10 Finland
Erysipelas
2.9
6.5
34
134
D01AC02
ATC
miconazole; topical
4.0
6.4
19
52
L40.0
ICD-10 Finland
Psoriasis vulgaris
5.4
6.1
17
34
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
21
55
4.22
7.51
3.1
2.2
—
—
—
0
0
20
55
3.99
6.70
3.1
1.7
—
—
—
0
0
57
315
2.22
5.31
4.1
3.7
818.29
253.29
ng/l
0.47
42
240
43
235
2.11
4.01
2.7
2.0
—
—
—
0
0
10
23
4.55
3.36
2.0
1.3
—
—
—
0
0
10
23
4.55
3.36
2.0
1.3
—
—
—
0
0
10
23
4.55
3.36
2.0
1.3
—
—
—
0
0
13
46
2.98
2.99
1.8
1.5
—
—
—
0
0
7
13
5.56
2.90
1.0
1.0
—
—
—
0
0
15
61
2.60
2.70
4.0
2.7
—
—
—
0
0
135
1149
1.85
2.69
9.9
8.5
77.13
78.26
u/l
0.17
130
1081
90
691
1.64
2.59
2.7
2.6
—
—
estimate
—
0
0
5
7
7.31
2.56
1.2
1.4
358.00
775.43
u/ml
—
5
7
22
114
2.07
2.33
3.1
2.5
0.79
0.12
e6/l
0.82
22
109
54
373
1.66
2.31
3.8
2.4
—
—
—
0
0
6
13
4.74
2.29
1.5
1.1
—
—
—
0
0
64
465
1.60
2.23
2.8
3.2
573.72
1033.10
ng/l
2.60
59
391
15
68
2.32
2.18
1.3
2.0
45.40
40.16
u/l
0.39
15
59
11
43
2.66
2.12
3.3
2.0
24.66
24.98
mmol/l
0.08
11
43
5
11
4.65
1.95
1.8
2.5
—
—
—
0
0
5
11
4.65
1.95
1.8
2.5
—
—
—
0
0
5
11
4.65
1.95
1.8
2.5
—
—
—
0
0
5
11
4.65
1.95
1.8
2.5
—
—
—
0
0
7
22
3.27
1.90
2.4
1.4
—
—
—
0
0
48
338
1.59
1.86
3.2
3.8
1.02
1.02
kg/l
0.31
37
220
80
631
1.51
1.86
5.9
4.5
36.12
35.91
g/l
0.12
73
600
7
23
3.13
1.82
2.4
1.3
—
—
—
0
0
7
23
3.13
1.82
2.4
1.3
—
—
—
0
0
11
47
2.43
1.82
2.0
1.5
1.17
1.20
g/l
0.09
11
47
7
24
3.00
1.74
2.9
1.6
—
—
—
0
0
47
335
1.56
1.73
2.0
1.6
0.90
1.47
mg/l
1.13
39
275
103
865
1.48
1.71
11.4
10.4
4.21
3.96
e9/l
0.53
86
751
11
51
2.24
1.54
2.0
1.2
—
—
—
0
0
5
15
3.40
1.53
1.8
2.3
—
—
—
0
0
5
15
3.40
1.53
1.0
1.1
—
—
—
0
0
5
15
3.40
1.53
1.8
2.3
—
—
—
0
0
5
15
3.40
1.53
1.8
2.3
—
—
—
0
0
7
27
2.66
1.53
2.9
1.6
—
—
—
0
0
7
27
2.66
1.53
1.1
1.2
—
—
—
0
0
50
371
1.49
1.51
2.9
2.1
1.86
2.98
mg/l
5.38
42
328
18
295
0.56
1.50
2.8
3.1
1.05
0.79
ug/l
0.50
13
178
18
103
1.84
1.47
2.1
1.3
—
—
—
0
0
9
39
2.38
1.45
4.3
1.9
—
—
—
0
0
10
46
2.25
1.43
2.2
1.5
0.21
0.23
g/l
—
10
46
5
18
2.83
1.29
4.6
1.9
—
—
—
0
0
82
685
1.38
1.27
2.9
2.5
77.40
76.68
nmol/l
0.09
74
602
5
19
2.68
1.22
1.4
1.6
—
—
—
0
0
26
177
1.55
1.16
2.7
1.9
—
—
—
0
0
80
679
1.34
1.07
2.4
2.1
84.12
95.05
pmol/l
1.17
39
343
123
1114
1.38
1.06
6.8
4.3
16.66
11.83
mm/h
2.33
118
1033
20
132
1.58
1.02
1.8
1.5
—
—
—
0
0
154
1456
1.61
1.01
20.6
14.8
26.33
22.35
mg/l
0.73
134
1177
7
35
2.04
1.01
4.3
1.5
—
—
—
0
0
62
518
1.31
0.90
4.5
4.1
6.90
10.98
mg/mmol
0.50
42
310
10
57
1.80
0.85
3.5
3.7
25.14
24.90
mmol/l
—
10
51
87
766
1.28
0.83
12.4
7.1
1.22
1.21
mmol/l
0.52
78
668
91
807
1.27
0.81
3.4
3.5
0.00
0.00
estimate
-0.00
15
149
6
33
1.85
0.80
2.5
1.5
—
—
—
0
0
78
683
1.26
0.76
3.5
2.9
104.98
122.75
ug/l
0.34
73
639
5
24
2.12
0.75
1.0
1.2
—
—
—
0
0
7
40
1.78
0.72
5.3
2.0
—
—
—
0
0
31
244
1.33
0.67
1.5
1.7
917.50
1133.94
nmol/l
0.79
25
182
99
900
1.24
0.67
3.1
2.8
—
—
—
0
0
9
141
0.62
0.63
47.1
8.0
1.06
1.29
mmol/l
—
9
141
8
51
1.60
0.61
4.0
4.0
86.05
182.43
mg/l
—
8
44
8
51
1.60
0.61
4.0
4.0
18.62
30.73
mg/l
—
8
44
67
589
1.23
0.61
3.0
3.4
0.00
0.02
estimate
0.50
11
125
8
54
1.50
0.58
1.4
1.3
—
2.65
—
0
10
6
36
1.69
0.57
2.0
1.5
—
—
—
0
0
90
819
1.21
0.57
3.4
3.5
0.00
2.22
estimate
0.50
15
135
33
269
1.28
0.57
1.4
1.3
2.77
5.67
u/ml
0.52
12
94
22
169
1.35
0.57
3.0
1.9
—
—
—
0
0
50
429
1.23
0.56
3.0
3.0
0.00
0.21
estimate
0.50
12
119
22
170
1.34
0.55
20.4
8.6
1.34
0.77
mmol/l
0.40
15
149
6
38
1.60
0.55
1.2
1.3
—
—
—
0
0
6
39
1.56
0.53
3.3
1.5
—
—
—
0
0
12
83
1.48
0.53
2.2
3.4
4.47
4.50
pmol/l
0.03
12
75
34
281
1.26
0.53
1.4
1.5
—
—
—
0
0
122
1151
1.21
0.50
5.1
4.2
14.35
14.79
pmol/l
1.24
117
1054
44
379
1.22
0.48
3.9
4.9
27.49
22.20
%
0.81
13
176
87
802
1.17
0.44
3.4
3.5
0.00
0.00
estimate
-0.00
15
149
5
31
1.63
0.43
3.6
2.1
—
—
—
0
0
5
31
1.63
0.43
1.4
1.5
—
—
—
0
0
5
31
1.63
0.43
1.4
1.5
—
—
—
0
0
0
18
0.00
0.40
0.0
1.1
—
—
—
0
0
0
18
0.00
0.40
0.0
1.1
—
—
—
0
0
5
35
1.44
0.39
1.4
1.4
—
—
—
0
0
145
1403
1.23
0.38
7.2
6.3
39.71
39.28
mmol/mol
0.27
140
1319
151
1467
1.26
0.37
6.1
5.2
1.40
1.47
mmol/l
1.72
145
1363
115
1205
0.86
0.37
22.8
18.8
13.48
13.62
%
0.89
115
1193
17
211
0.78
0.37
31.3
7.2
104.47
104.27
mmol/l
0.07
17
211
5
76
0.65
0.36
1.4
1.0
—
—
—
0
0
6
87
0.68
0.34
11.0
2.3
1.02
1.18
%
—
6
87
76
705
1.14
0.33
10.5
6.3
1.21
1.22
mmol/l
0.05
69
653
10
132
0.74
0.33
2.3
3.3
—
—
—
0
0
58
531
1.14
0.31
4.1
3.2
—
—
—
0
0
146
1421
1.19
0.30
18.7
15.0
83.41
80.91
ml/min/173m2
0.77
132
1318
41
367
1.15
0.30
1.5
1.2
1.12
1.12
u/ml
0.01
13
94
72
678
1.11
0.23
3.2
1.9
1.50
1.39
mmol/l
0.71
64
567
5
39
1.29
0.23
1.2
1.9
—
—
—
0
0
5
40
1.26
0.22
1.4
1.4
—
—
—
0
0
15
177
0.83
0.22
4.3
7.1
—
—
—
0
0
8
102
0.77
0.22
46.2
10.9
94.54
93.78
%
—
8
102
0
10
0.00
0.21
0.0
1.7
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
1.26
—
0
5
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
14
117
1.21
0.21
1.9
2.8
84.67
68.33
ml/min/173m2
—
6
52
46
425
1.11
0.21
3.3
3.4
0.00
0.01
estimate
0.50
13
134
0
13
0.00
0.21
0.0
1.0
—
—
—
0
0
6
48
1.26
0.20
1.5
1.8
—
—
—
0
0
15
127
1.20
0.20
2.2
2.3
—
—
—
0
0
22
248
0.87
0.19
2.5
3.2
8.68
2.34
e6/l
—
8
120
11
91
1.22
0.18
1.6
1.8
—
—
—
0
0
16
139
1.17
0.17
2.3
2.4
—
—
—
0
0
24
265
0.89
0.16
2.3
3.0
2.64
0.80
e6/l
—
10
135
44
464
0.93
0.12
2.0
1.7
19.60
21.11
nmol/l
0.28
37
383
6
55
1.09
0.09
1.2
1.2
1.63
1.55
g/l
—
6
55
6
57
1.05
0.08
1.2
1.2
0.78
0.93
g/l
—
6
57
5
60
0.83
0.08
1.6
1.8
27.92
4.61
mg/l
—
5
44
5
62
0.80
0.08
2.6
2.7
—
—
—
0
0
7
67
1.05
0.08
2.4
1.3
—
—
—
0
0
6
70
0.85
0.08
2.0
1.3
—
—
—
0
0
146
1445
1.07
0.07
6.6
5.1
6.02
5.96
mmol/l
0.23
138
1335
12
129
0.92
0.03
7.0
2.5
4.27
4.60
kpa
0.37
12
124
28
288
0.97
0.02
1.6
1.4
55.39
33.27
iu/ml
0.30
14
100
59
582
1.02
0.01
3.5
3.7
1274.58
32.48
ng/l
0.49
38
401
24
239
1.00
0.00
1.8
1.4
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
4.7
—
0.33
—
0
6
0
6
0.00
0.00
0.0
1.5
—
—
—
0
0
6
61
0.98
0.00
4.5
1.2
10.40
10.15
g/l
—
6
56
0
6
0.00
0.00
0.0
1.3
—
12.72
—
0
6
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
3.2
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
3.6
—
4.66
—
0
9
5
53
0.94
-0.00
2.2
2.6
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
56.20
—
0
5
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.4
—
28.63
—
0
9
7
70
1.00
-0.00
2.7
3.6
344.29
3439.04
u/ml
—
7
64
0
7
0.00
-0.00
0.0
5.1
—
201.00
—
0
7
9
97
0.92
-0.00
1.3
1.5
—
51.37
—
0
11
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
12.60
—
0
5
0
5
0.00
-0.00
0.0
3.8
—
43.26
—
0
5
0
5
0.00
-0.00
0.0
1.8
—
7.18
—
0
5
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
30.58
—
0
9
43
430
1.00
-0.00
2.9
3.2
0.49
0.40
e6/l
0.11
30
304
0
9
0.00
-0.00
0.0
3.6
—
10.77
—
0
9
Mortality – FinRegistry
↥Association
Association between endpoint L12_ACQKERAT and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| L12_ACQKERAT | 1.483 [1.05, 2.09] | 0.025 |
| Birth year | 0.991 [0.98, 1.0] | 0.053 |
During the follow-up period (1.1.1998 — 31.12.2019), 57 out of 400 females with L12_ACQKERAT died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| L12_ACQKERAT | 1.494 [1.12, 2.0] | 0.007 |
| Birth year | 0.987 [0.98, 1.0] | 0.011 |
During the follow-up period (1.1.1998 — 31.12.2019), 53 out of 297 males with L12_ACQKERAT died.
Mortality risk
Mortality risk for people of age
years, who have L12_ACQKERAT.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.085% | 0.303% |
| 5 | 0.719% | 1.604% |
| 10 | 1.966% | 4.021% |
| 15 | 3.781% | 7.835% |
| 20 | 6.415% | 13.288% |
Relationships between endpoints
↥Index endpoint: L12_ACQKERAT – Acquired keratosis [keratoderma] palmaris et plantaris
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data